Package Insert: Information for the User
Kisplyx 4 mg Hard Capsules
Kisplyx 10 mg Hard Capsules
Lenvatinib
Read this package insert carefully before you start taking this medicine, because it contains important information for you.
What is Kisplyx
Kisplyx is a medication that contains the active ingredient lenvatinib. It is used in combination with pembrolizumab as a first-line treatment for adults with advanced kidney cancer (advanced renal cell carcinoma). It is also used in combination with everolimus to treat adult patients with advanced kidney cancer when other treatments (called vascular endothelial growth factor (VEGF) targeted therapies) have not helped to stop the disease.
How Kisplyx works
Kisplyx blocks the action of proteins called receptor tyrosine kinases (RTK), which are involved in the development of new blood vessels that carry oxygen and nutrients to cells and help them grow. These proteins may be present in large quantities in cancer cells, and by blocking their action, Kisplyx can slow down the rate at which cancer cells multiply and the tumor grows, and help cut off the blood supply that cancer cells need.
Do not take Kisplyx:
Warnings and precautions
Consult your doctor before starting to take Kisplyx if:
Before starting to take Kisplyx, your doctor may perform some blood tests, for example, to check your blood pressure and renal or hepatic function, and to see if you have low sodium levels and high thyroid-stimulating hormone levels in your blood. Your doctor will discuss the results of these tests with you and decide if you can be given Kisplyx. You may need to receive additional treatment with other medications, reduce the dose of Kisplyx, or take extra precautions due to an increased risk of adverse effects.
In case of doubt, consult your doctor before taking Kisplyx.
Children and adolescents
Kisplyx is not currently recommended for use in children and adolescents under 18 years of age.
Other medications and Kisplyx
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. This includes herbal medications and over-the-counter medications.
Contraception, pregnancy, and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Kisplyx may cause side effects that may affect your ability to drive or operate machinery. Avoid driving or operating machinery if you feel dizzy or tired.
Follow exactly the administration instructions of this medication indicated by your doctor.
In case of doubt, consult your doctor or pharmacist again.
How much to take
Medication intake
For how long should you take Kisplyx
You will generally continue to take this medication as long as you continue to receive clinical benefits.
If you take more Kisplyx than you should
If you take more Kisplyx than you should, consult your doctor or pharmacist immediately. Bring the medication packaging with you.
If you forgot to take Kisplyx
Do not take a double dose (two doses at the same time) to compensate for the missed doses.
The schedule you should follow if you forget to take a dose will depend on how much time is left until your
next dose.
If there are 12 hours or more until your next dose, take the missed dose as soon as you remember. Then take the next dose at the usual time.
If there are less than 12 hours until your next dose, omit the missed dose. Then take the next dose at the usual time.
Like all medicines, this medicine can cause side effects, although not everyone will experience them. The following side effects may occur with this medicine.
Inform your doctor immediately if you experience any of the following side effects,
you may need urgent medical attention:
Inform your doctor immediately if you experience any of the side effects mentioned below.
The following side effects may occur when the medicine is administered as monotherapy:
Very common(may affect more than 1in 10people):
Common(may affect up to 1in 10people):
Rare(may affect up to1 in 100people):
Unknown frequency(the following side effects have been reported since the commercialization ofKisplyx, but the frequency with which they occur is unknown):
The following side effects may occur when the medicine is administered in combination with everolimus:
Very common(may affect more than 1in 10people):
Common(may affect up to 1in 10people):
Rare(may affect up to1 in 100people):
Unknown frequency(the following side effects have been reported since the commercialization ofKisplyx, but the frequency with which they occur is unknown):
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSistema Español de Farmacovigilancia de Medicamentos de uso Humano:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Composition of Kisplyx
Appearance of the product and contents of the pack
Marketing Authorization Holder
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
Email: [email protected]
Responsible Person for Manufacture
Eisai GmbH
Edmund-Rumpler-Straße 3
60549 Frankfurt am Main
Germany
For further information about this medicinal product, please consult the representative of the marketing authorisation holder in your country:
België/Belgique/Belgien Eisai SA/NV Tel/Tel: +32 (0) 800 158 58 | Lietuva Ewopharma AG atstovybe Tel: + 370 5 2430444 |
Luxembourg/Luxemburg Eisai SA/NV Tél/Tel: +32 (0) 800 158 58 (Belgique/Belgien) | Lietuva Ewopharma AG atstovybe Tel: + 370 5 2430444 |
Ceská republika Eisai GesmbH organizacni složka Tel.: + 420 242 485 839 | Magyarország Ewopharma Hungary Ltd. Tel.: + 36 1 200 46 50 |
Danmark Eisai AB Tlf: + 46 (0) 8 501 01 600 (Sverige) | Malta Cherubino LTD Tel.: + 356 2134270 |
Deutschland Eisai GmbH Tel: + 49 (0) 69 66 58 50 | Nederland Eisai B.V. Tel: + 31 (0) 900 575 3340 |
Eesti Ewopharma AG Eesti filiaal Tel: + 372 6015540 | Norge Eisai AB Tlf: + 46 (0) 8 501 01 600 (Sverige) |
Ελλ?δα Arriani Pharmaceutical S.A. Τηλ: + 30 210 668 3000 | Österreich Eisai GesmbH Tel: + 43 (0) 1 535 1980-0 |
España Eisai Farmacéutica, S.A. Tel: + (34) 91 455 94 55 | Polska Ewopharma AG Sp. z.o.o Tel: + 48 (22) 620 11 71 |
France Eisai SAS Tél: + (33) 147 67 00 05 | Portugal Eisai Farmacêutica, Unipessoal Lda Tel: + 351 214 875 540 |
Hrvatska Ewopharma d.o.o Tel: + 385 (0) 1 6646 563 Ireland Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) | România Ewopharma AG Tel: + 40 21 260 13 44 Slovenija Ewopharma d.o.o. Tel: + 386 590 848 40 |
Ísland Eisai AB Sími: + 46 (0) 8 501 01 600 (Svíþjóð) | Slovenská republika Eisai GesmbH organizacní složka Tel.: +420 242 485 839 (Ceská republika) |
Italia Eisai S.r.l. Tel: + 39 02 5181401 | Suomi/Finland Eisai AB Puh/Tel: + 46 (0) 8 501 01 600 (Ruotsi/Sverige) |
Κ?προς Arriani Pharmaceuticals S.A. Τηλ: + 30 210 668 3000 (Ελλ?δα) | Sverige Eisai AB Tel: + 46 (0) 8 501 01 600 |
Latvija Ewopharma AG Parstavnieciba Tel: + 371 67450497 | United Kingdom (Northern Ireland) Eisai GmbH Tel: + 49 (0) 69 66 58 50 (Germany) |
Last update of the summary of product characteristics:
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.